Targeting the eIF4F translation initiation complex for cancer therapy.

Area of Science:

• Molecular Biology
• Oncology
• Cancer Therapeutics

Background:

• The eukaryotic translation initiation factor 4E (eIF4E) is frequently overactive in human cancers, correlating with disease progression.
• eIF4E hyperactivation drives cellular transformation and malignancy by enhancing the eIF4F translation initiation complex assembly.
• This leads to increased cap-dependent translation, disproportionately affecting mRNAs encoding proteins crucial for cancer hallmarks.

Purpose of the Study:

• To investigate the role of eIF4E and the eIF4F complex in cancer progression.
• To explore the therapeutic potential of targeting this complex in cancer treatment.
• To highlight the selective vulnerability of tumor cells to eIF4F inhibition.

Main Methods:

• Analysis of eIF4E function and its relation to cancer progression in human cancers and experimental models.
• Examination of the impact of altered eIF4F activity on the translation of specific mRNA pools.
• Review of recent advances in targeting the eIF4F complex for cancer therapy.

Main Results:

• Elevated eIF4E function is linked to enhanced translation of mRNAs encoding angiogenesis factors, oncoproteins, pro-survival proteins, and metastasis-associated proteins.
• These include key proteins like VEGF, c-myc, survivin, and MMP-9.
• Tumor cells exhibit heightened susceptibility to inhibition of the eIF4F complex.

Conclusions:

• Targeting eIF4E and the eIF4F translation initiation complex is a viable and attractive strategy for cancer therapy.
• These findings support the development of eIF4E-specific therapies, with the first already advanced to clinical trials.